Characterization of modified bovine haemoglobin by molecular filtration and electrophoresis in gradient gels

Fortová, H; Suttnar, Jiřı́; Kramlová, M.; Přistoupil, T.I.

doi:10.1016/s0021-9673(01)95836-4

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since pyridoxalation and other treatments can successfully correct the P 50 of Hb, combinations of such treatments and polymerization were explored, leading to the commercial development of a polymerized pyridoxalated human Hb (section IV.I). However, pyridoxal phosphate and glutaraldehyde compete for the same amino sites of Hb, and the combination of the two modifications adds further complexity to the product. ,,,− Combinations of NFPLP and glutaraldehyde treatment of Hb have also been investigated . Finally, whether polymerization suffices to prevent vasoconstriction is highly controversial (section IV.H).…”

Section: Polymerizationmentioning

confidence: 99%

“…However, pyridoxal phosphate and glutaraldehyde compete for the same amino sites of Hb, and the combination of the two modifications adds further complexity to the product. 522,524,706,[796][797][798] Combinations of NFPLP and glutaraldehyde treatment of Hb have also been investigated. 799 Finally, whether polymerization suffices to prevent vasoconstriction is highly controversial (section IV.H).…”

Section: Polymerizationmentioning

confidence: 99%

See 1 more Smart Citation

Oxygen Carriers (“Blood Substitutes”)Raison d'Etre, Chemistry, and Some PhysiologyBlut ist ein ganz besondrer Saft

2001

View full text Add to dashboard Cite

Pharmaceutical Corporation in San Diego; however, the opinion expressed here are solely his and not necessarily those of the Corporation. Jean G. Riess received his chemical engineer and doctorat-e `s-sciences degrees (the latter with Professor Guy Ourisson in 1963) from the University of Strasbourg. He then spent two years with John Van Wazer at Monsanto in Saint-Louis, MO, learning some phosphorus and transitionmetal chemistry. In 1968 he became Professor at the University of Nice, France, where he founded, directed, and eventually became honorary director of the Unite ´de Chimie Mole ´culaire (associated with the Centre National de la Recherche Scientifique). His research successively involved phosphorus chemistry, transition-metal chemistry, organometallics, and eventually perfluorochemicals. His present interests are in fluorocarbons, fluorinated amphiphiles, and their colloid chemistry, including fluorocarbon emulsions for in vivo O 2 delivery, fluorinated self-assemblies, and drug delivery systems. Professor Riess has published about 360 papers and holds ca. 25 patents. He has served on numerous councils and committees and has chaired or co-chaired international conferences on phosphorus chemistry and blood substitutes. He has won awards from the French Academy of Sciences, French Chemical Society, Alexander von Humboldt Stifftung, City of Nice and Controlled Release Society, as well as Alliance's first Distinguished Contribution Award. He holds an honorary Research Associate position at the University of California at San Diego and sits on the Board of Directors of Alliance Pharmaceutical Corp.

show abstract